Loss of inhibition over master pathways of bone mass regulation results in osteosclerotic bone metastases in prostate cancer

Swiss Medical Weekly

Volumn 139, Issue 15-16, 2009, Pages 220-225

  Rentsch, Cyrill A ^a   Cecchini, Marco G ^a   Thalmann, George N ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Bone metastases; Bone morphogenetic proteins; Metastases; Noggin; Osteosclerotic; Prostate cancer; WNT

Indexed keywords

ATRASENTAN; BONE MORPHOGENETIC PROTEIN; NOGGIN; WNT PROTEIN; CARRIER PROTEIN; NOGGIN PROTEIN;

BONE MASS; BONE METASTASIS; BONE REMODELING; CARCINOGENESIS; CLINICAL TRIAL; HUMAN; INHIBITION KINETICS; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOSCLEROSIS; PROSTATE CANCER; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; ANIMAL MODEL; BONE TUMOR; DRUG ANTAGONISM; MALE; METASTASIS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATE TUMOR;

ANIMALS; BONE MORPHOGENETIC PROTEINS; BONE NEOPLASMS; BONE REMODELING; CARRIER PROTEINS; HUMANS; MALE; MODELS, ANIMAL; OSTEOBLASTS; OSTEOSCLEROSIS; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 67449094018     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Ries LAG MD, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, Mariotto A, Miller BA, Feuer EJ, Altekruse SF, Lewis DR, Clegg L, Eisner MP, Reichman M, Edwards BK (eds). SEER Cancer Statistics Review, 1975-2005. 2008 [cited; Available from: http://seer.cancer.gov/csr/1975-2005/
2. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433-439 (Pubitemid 41124175)
3. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin. 1999;49:8-31, 1.
4. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352:1977-1984 (Pubitemid 40638368)
5. Goktas S, Crawford ED. Optimal hormonal therapy for advanced prostatic carcinoma. Semin Oncol. 1999;26:162-173
6. Bubendorf L, Schopfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000;31:578-583 (Pubitemid 30323983)
7. Shulman MJ, Benaim EA. The natural history of androgen independent prostate cancer. J Urol. 2004;172:141-145 (Pubitemid 41615056)
8. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458-1468
9. Perk H, Yildiz M, Kosar A, et al. Correlation between BMD and bone scintigraphy in patients with prostate cancer. Urol Oncol. 2008;26:250-253 (Pubitemid 351608584)
10. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96:879-882 (Pubitemid 38807610)
11. Eriksen E, Axelrod D, Melsen F. Bone histomorphometry. New York: Raven Press; 1994.
12. Harada S, Rodan GA. Control of osteoblast function and regulation of bone mass. Nature. 2003;423:349-355 (Pubitemid 40852710)
13. Vaananen HK, Laitala-Leinonen T. Osteoclast lineage and function. Arch Biochem Biophys. 2008;473:132-138
14. Elefteriou F. Regulation of bone remodeling by the central and peripheral nervous system. Arch Biochem Biophys. 2008;473: 231-236
15. Hofstetter W, Felix R, Cecchini M. Colony-stimulating factors. San Diego: Academic Press; 1996.
16. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165-176 (Pubitemid 28180851)
17. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesisinhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci. U S A 1998;95:3597-3602 (Pubitemid 28173173)
18. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309-319 (Pubitemid 27199902)
19. Yasuda H, Shima N, Nakagawa N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology. 1998;139:1329-1337 (Pubitemid 28510154)
20. Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys. 2008;473:139-146
21. Mak KK, Bi Y, Wan C, et al. Hedgehog signaling in mature osteoblasts regulates bone formation and resorption by controlling PTHrP and RANKL expression. Dev Cell. 2008;14: 674-688 (Pubitemid 351622607)
22. Tsukii K, Shima N, Mochizuki S, et al. Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone. Biochem Biophys Res Commun. 1998;246:337-341 (Pubitemid 28412599)
23. Hauschka PV, Mavrakos AE, Iafrati MD, Doleman SE, Klagsbrun M. Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. J Biol Chem. 1986;261:12665-12674 (Pubitemid 17204223)
24. Jung Y, Song J, Shiozawa Y, et al. Hematopoietic Stem Cells Regulate Mesenchymal Stromal Cell Induction into Osteoblasts Thereby Participating in The Formation of the Stem Cell Niche. Stem Cells. 2008.
25. Kaigler D, Krebsbach PH, West ER, Horger K, Huang YC, Mooney DJ. Endothelial cell modulation of bone marrow stromal cell osteogenic potential. FASEB J. 2005;19:665-667 (Pubitemid 40471279)
26. Percival RC, Urwin GH, Harris S, et al. Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol. 1987;13:41-49 (Pubitemid 17040425)
27. Koga H, Naito S, Koto S, et al. Use of bone turnover marker, pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP), in the assessment and monitoring of bone metastasis in prostate cancer. Prostate. 1999;39:1-7. (Pubitemid 29143102)
28. Matsuo K, Irie N. Osteoclast-osteoblast communication. Arch Biochem Biophys. 2008;473:201-209
29. Roudier MP, Morrissey C, True LD, Higano CS, Vessella RL, Ott SM. Histopathological assessment of prostate cancer bone osteoblastic metastases. J Urol. 2008;180:1154-1160
30. de Vernejoul MC. Sclerosing bone disorders. Best Pract Res Clin Rheumatol. 2008;22:71-83.
31. Balemans W, Patel N, Ebeling M, et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet. 2002;39:91-97 (Pubitemid 34146376)
32. Brunkow ME, Gardner JC, Van Ness J, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001;68:577-589 (Pubitemid 32202753)
33. Semenov M, Tamai K, He X. SOST is a ligand for LRP5/ LRP6 and a Wnt signaling inhibitor. J Biol Chem. 2005;280: 26770-26775 (Pubitemid 41040710)
34. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004;20:781-810. (Pubitemid 39488658)
35. Hall CL, Kang S, MacDougald OA, Keller ET. Role of Wnts in prostate cancer bone metastases. J Cell Biochem. 2006;97: 661-672
36. Krishnan V, Bryant HU, Macdougald OA. Regulation of bone mass by Wnt signaling. J Clin Invest. 2006;116:1202-1209
37. Glass DA, 2nd, Bialek P, Ahn JD, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005;8:751-764
38. Sun P, Xiong H, Kim TH, Ren B, Zhang Z. Positive inter-regulation between beta-catenin/T cell factor-4 signaling and endothelin- 1 signaling potentiates proliferation and survival of prostate cancer cells. Mol Pharmacol. 2006;69:520-531 (Pubitemid 43121949)
39. Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin- 1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995;1:944-949
40. Stern PH, Tatrai A, Semler DE, et al. Endothelin receptors, second messengers, and actions in bone. J Nutr. 1995;125: 2028S-32S.
41. Boyden LM, Mao J, Belsky J, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med. 2002;346:1513-1521 (Pubitemid 34755690)
42. Janssens K, Gershoni-Baruch R, Guanabens N, et al. Mutations in the gene encoding the latency-associated peptide of TGF-beta 1 cause Camurati-Engelmann disease. Nat Genet. 2000;26:273-275 (Pubitemid 30824604)
43. Shore EM, Xu M, Feldman GJ, et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet. 2006;38: 525-527
44. Hellemans J, Preobrazhenska O, Willaert A, et al. Loss-of-function mutations in LEMD3 result in osteopoikilosis, Buschke-Ollendorff syndrome and melorheostosis. Nat Genet. 2004;36:1213-1218
45. Canalis E, Deregowski V, Pereira RC, Gazzerro E. Signals that determine the fate of osteoblastic cells. J Endocrinol Invest. 2005;28:3-7.
46. Zhao G. Consequences of knocking out BMP signaling in the mouse. Genesis. 2003;35:43-56. (Pubitemid 36150981)
47. de Caestecker M. The transforming growth factor-beta super-family of receptors. Cytokine Growth Factor Rev. 2004;15: 1-11. (Pubitemid 38121286)
48. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003; 425:577-584 (Pubitemid 37280136)
49. Wan M, Cao X. BMP signaling in skeletal development. Biochem Biophys Res Commun. 2005;328:651-657
50. Brunet LJ, McMahon JA, McMahon AP, Harland RM. Noggin, cartilage morphogenesis, and joint formation in the mammalian skeleton. Science. 1998;280:1455-1457 (Pubitemid 28264842)
51. Zhang D, Ferguson CM, O'Keefe RJ, Puzas JE, Rosier RN, Reynolds PR. A role for the BMP antagonist chordin in endochondral ossification. J Bone Miner Res. 2002;17:293-300. (Pubitemid 34087662)
52. Wu XB, Li Y, Schneider A, et al. Impaired osteoblastic differentiation, reduced bone formation, and severe osteoporosis in Noggin-overexpressing mice. J Clin Invest. 2003;112:924-934 (Pubitemid 38063750)
53. Gazzerro E, Pereira RC, Jorgetti V, Olson S, Economides AN, Canalis E. Skeletal overexpression of gremlin impairs bone formation and causes osteopenia. Endocrinology. 2005;146: 655-665 (Pubitemid 40129821)
54. Gazzerro E, Gangji V, Canalis E. Bone morphogenetic proteins induce the expression of Noggin, which limits their activity in cultured rat osteoblasts. J Clin Invest. 1998;102:2106-2114 (Pubitemid 29018817)
55. Komori T, Yagi H, Nomura S, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell. 1997;89:755-764 (Pubitemid 27516178)
56. Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003;349:2483-2494 (Pubitemid 38010074)
57. Hall CL, Daignault SD, Shah RB, Pienta KJ, Keller ET. Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis. Prostate 2008.
58. Schwaninger R, Rentsch CA, Wetterwald A, et al. Lack of Noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases. Am J Pathol. 2007;170: 160-175 (Pubitemid 47339197)
59. Hall CL, Bafico A, Dai J, Aaronson SA, Keller ET. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res. 2005;65:7554-7560 (Pubitemid 41297224)
60. Chen G, Shukeir N, Potti A, et al. Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer. 2004;101:1345-1356 (Pubitemid 39180390)
61. Emami KH, Corey E. When prostate cancer meets bone: control by wnts. Cancer Lett. 2007;253:170-179 (Pubitemid 47023104)
62. Jung K, Stephan C, Semjonow A, Lein M, Schnorr D, Loening SA. Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer. J Urol. 2003;170:2302-2305 (Pubitemid 37413980)
63. Brown JM, Corey E, Lee ZD, et al. Osteoprotegerin and rank ligand expression in prostate cancer. Urology. 2001;57:611-616
64. Corey E, Brown LG, Kiefer JA, et al. Osteoprotegerin in prostate cancer bone metastasis. Cancer Res. 2005;65:1710-1718 (Pubitemid 40478596)
65. Clines GA, Mohammad KS, Bao Y, et al. Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. Mol Endocrinol. 2007;21:486-498 (Pubitemid 46184897)
66. Yin JJ, Mohammad KS, Kakonen SM, et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci. U S A 2003;100:10954-10959 (Pubitemid 37140134)
67. Granchi S, Brocchi S, Bonaccorsi L, et al. Endothelin-1 production by prostate cancer cell lines is up-regulated by factors involved in cancer progression and down-regulated by androgens. Prostate. 2001;49:267-277 (Pubitemid 33117002)
68. Rentsch CA, Cecchini MG, Schwaninger R, et al. Differential expression of TGFbeta-stimulated clone 22 in normal prostate and prostate cancer. Int J Cancer. 2005.
69. Dai J, Keller J, Zhang J, Lu Y, Yao Z, Keller ET. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res. 2005;65: 8274-8285 (Pubitemid 41330592)
70. Dai J, Hall CL, Escara-Wilke J, Mizokami A, Keller JM, Keller ET. Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms. Cancer Res. 2008;68:5785-5794
71. Carducci MA, Saad F, Abrahamsson PA, et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer. 2007;110:1959-1966 (Pubitemid 350036854)
72. Nelson JB, Love W, Chin JL, et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone- refractory prostate cancer. Cancer. 2008;113:2478-2487
73. Tu SM, Lin SH. Current trials using bone-targeting agents in prostate cancer. Cancer J. 2008;14:35-39